Harnessing natural killer cells to combat chemotherapy resistance

forthcoming

Chemotherapy resistance remains a major challenge in cancer treatment, often leading to poor patient outcomes. NatK aims to (1) identify predictive signature of chemoresistance and (2) develop innovative therapeutic strategies to overcome it, using triple negative breast cancer (TNBC) as a model. The focus is on natural killer (NK) cells, hypothesising that reactivating these cells could enhance their cytotoxicity against chemoresistant tumours. State-of-the-art 10X Visium spatial transcriptomics will be employed to analyse primary TNBC samples from chemotherapy responders and non-responders, mapping NK cell infiltration and activity within the tumour microenvironment (TME). Advanced bioinformatics will identify immune-related signatures of chemoresistance, validated in independent patient cohorts to develop a robust NK cell-related biomarker for patient stratification. To translate these findings into therapeutic strategies, specific genes upregulated in chemoresistant tumours will be targeted to enhance NK cell-mediated cytotoxicity. Co-culture systems with NK cells and patient-derived organoids will be used to evaluate the impact of gene modulation, followed by the development of small molecule inhibitors targeting promising candidates. The efficacy of combining NK cell activation with chemotherapy will then be assessed both in vitro and in vivo, aiming to establish a novel combination therapy to combat chemoresistance. NatK integrates state-of-the-art spatial transcriptomics, functional immune profiling and patient-derived organoid models to elucidate chemoresistance mechanisms. The insights gained may have broader implications, potentially extending to other cancer types and guiding targeted immunotherapy development. In line with the MSCA Postdoctoral Fellowship objectives, this interdisciplinary research will advance expertise in cutting-edge biomedical technologies, foster international collaboration, and contribute to advancing oncology in Europe.